(Q39404712)

11 September 2017

title

Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit (English)

1 reference

11 September 2017

0 references

Robert B Berkowitz

1

1 reference

11 September 2017

George G Woodworth

2

1 reference

11 September 2017

Cheryl Lutz

3

1 reference

11 September 2017

Kay Weiler

4

1 reference

11 September 2017

John Weiler

5

1 reference

11 September 2017

Madelyn Moss

6

1 reference

11 September 2017

Suzanne Meeves

7

1 reference

11 September 2017

publication date

1 July 2002

1 reference

Annals of Allergy, Asthma & Immunology

11 September 2017

published in

1 reference

11 September 2017

volume

89

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

38-45

1 reference

Allergic rhinitis: epidemiology and natural history.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Overview of comorbid associations of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Complications of allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Quality-of-life outcomes measures of asthma and allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

The effects of antihistamines on cognition and performance

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

Measuring health-related quality of life in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961909-6

7 January 2021

10.1016/S1081-1206(10)61909-6

Identifiers

DOI

1 reference

11 September 2017

1 reference